Start page Newsroom Newsroom-listing Newsroom type All Releases Articles year All years 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 Inke Tirkkonen: The Phase1 trainee programme has allowed me to experience how work in drug safety requires great precision and that it is also highly relevant and meaningful 9/29/2023 We are Orion Internal mobility has enabled Ville, Master of Science in mechanical engineering, to have a varied career at Orion 9/29/2023 We are Orion Maija Väätäjä: The people and truly meaningful work have been the best aspects of Orion’s Phase1 trainee programme 9/21/2023 We are Orion What is a generic medicine – and what is good to know about it? 9/21/2023 Your Health Change in Orion Group's Half-Year Financial Report 2024 publication date 9/20/2023 Stock exchange release Damla Serper: As a Phase1 trainee, I have been happy to work on a project where I can integrate my research into industrial set-up 9/15/2023 We are Orion Even a short job rotation period can be invigorating and develop professional skills 9/14/2023 We are Orion A biosimilar has the same efficacy and safety as a biological proprietary drug 9/12/2023 Your Health Finland’s good reputation attracted Bryce Nelson to work in Finland 9/7/2023 We are Orion Can Hekim studies mechanisms that help the human immune system defend itself against cancer 9/5/2023 We are Orion 24 000 Orion Corporation A shares converted into B shares 9/4/2023 Stock exchange release The popular Phase1 trainee programme offers university students a sense of community and professionally challenging tasks 9/1/2023 We are Orion Orion Corporation: Managers’ transactions – Hilpi Rautelin 8/30/2023 Managers transactions Change in Orion Group Executive Management Board as of February 1st, 2024 – Julia Macharey appointed Senior Vice President, People & Culture 8/22/2023 Stock exchange release Orion has started building a virtual pharmaceutical research ecosystem in Finland 8/22/2023 Science and Partnering Versatile and talented Tapani returned to Orion after many years equipped with lessons learnt from the banking world 8/18/2023 We are Orion European Commission approval of Ztalmy® (ganaxolone) for the adjunctive treatment of epileptic seizures associated with CDKL5 deficiency disorder 7/31/2023 Press release Orion Corporation: Managers’ transactions – Kari Jussi Aho 7/27/2023 Managers transactions
